Biocept Inc. (blood-based molecular diagnostics for solid tumors) netted $8.7mm through the sale of 4.3mm common shares at $2.15 (a slight discount) to institutional investors. The placement included five-year warrants to buy another 2.16mm shares at $2.50. Roth Capital Partners, WestPark Capital, and Chardan Capital were the placement agents. (Mar.)
Investment Banks/Advisors: Chardan Capital Markets; Roth Capital Partners; WestPark Capital Inc.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?